stoxline Quote Chart Rank Option Currency Glossary
  
Novavax, Inc. (NVAX)
15.02  -0.83 (-5.24%)    07-18 15:52
Open: 15.96
High: 16.89
Volume: 7,802,624
  
Pre. Close: 15.85
Low: 14.74
Market Cap: 2,109(M)
Technical analysis
2024-07-18 3:22:08 PM
Short term     
Mid term     
Targets 6-month :  19.96 1-year :  23.31
Resists First :  17.09 Second :  19.96
Pivot price 13.31
Supports First :  13.74 Second :  11.68
MAs MA(5) :  15.06 MA(20) :  13.44
MA(100) :  9.31 MA(250) :  7.48
MACD MACD :  0.3 Signal :  0
%K %D K(14,3) :  76.5 D(3) :  80.8
RSI RSI(14): 55.8
52-week High :  23.86 Low :  3.52
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NVAX ] has closed below upper band by 24.0%. Bollinger Bands are 20.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.57 - 16.66 16.66 - 16.71
Low: 14.99 - 15.1 15.1 - 15.16
Close: 15.69 - 15.86 15.86 - 15.96
Company Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Headline News

Thu, 18 Jul 2024
Analysts Expect Novavax, Inc. (NASDAQ:NVAX) To Breakeven Soon - Simply Wall St

Thu, 18 Jul 2024
FY2026 Earnings Forecast for Novavax, Inc. Issued By Zacks Research (NASDAQ:NVAX) - MarketBeat

Wed, 17 Jul 2024
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Wed, 17 Jul 2024
Novavax (NASDAQ:NVAX) Shares Gap Up to $13.11 - Defense World

Wed, 17 Jul 2024
Novavax (NASDAQ:NVAX) Shares Gap Up to $13.11 - American Banking and Market News

Tue, 16 Jul 2024
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 147 (M)
Shares Float 122 (M)
Held by Insiders 4.9 (%)
Held by Institutions 58.2 (%)
Shares Short 39,710 (K)
Shares Short P.Month 45,290 (K)
Stock Financials
EPS -3.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -6.18
Profit Margin -40.1 %
Operating Margin -147.9 %
Return on Assets (ttm) -16.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 15.8 %
Gross Profit (p.s.) 0
Sales Per Share 6.76
EBITDA (p.s.) -2.27
Qtrly Earnings Growth 0 %
Operating Cash Flow -472 (M)
Levered Free Cash Flow -1,200 (M)
Stock Valuations
PE Ratio -4.86
PEG Ratio 0.6
Price to Book value -2.4
Price to Sales 2.19
Price to Cash Flow -4.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android